Emcure Pharmaceuticals jumps as Q2 net profit rises 29% YoY
Revenue from operations increased 24.3% year on year and 9.3% quarter on quarter to Rs 2,820.5 crore in Q2 FY27.
EBITDA increased 30.9% year on year and 13.1% quarter on quarter to Rs 574.8 crore. EBITDA margin expanded to 20.4% from 19.3% in Q2 FY26 and 19.7% in Q1 FY27.
Gross profit increased 21.6% year on year and 11.3% sequentially to Rs 1,678.1 crore. Gross profit margin stood at 59.5%, down 131 basis points year on year but up 108 basis points quarter on quarter.
Profit before tax stood at Rs 445.9 crore in Q2 FY27, up 13.3% vs previous quarter and 30.6% vs year-ago quarter.
International revenue increased 34.5% year on year to Rs 1,665.2 crore, while domestic revenue grew 12% to Rs 1,155.3 crore. Within the international business, revenue from the rest of the world rose 41.1% year on year to Rs 629.7 crore, Europe increased 36% to Rs 604.3 crore and Canada grew 24% to Rs 431.2 crore.
Net cash generated from operations stood at Rs 723.5 crore in H1 FY27, compared with Rs 256.2 crore in H1 FY26.
As of 30 September 2026, gross debt stood at Rs 1,467.3 crore, while cash and liquid investments totalled Rs 150.2 crore. Net debt stood at Rs 1,317.1 crore. The company attributed the increase in debt to Mantra earnout and Gennova consolidation payments.
Following the annual general meeting held on 21 September 2026, Satish Mehta has assumed the role of chairman of the board, in addition to his existing positions as managing director and CEO.
Emcure Pharmaceuticals is a Pune-based pharmaceutical company engaged in developing, manufacturing and marketing medicines across major therapeutic areas. Established in 1981, it operates in more than 80 countries, including Europe and Canada, and ranked 13th in India by domestic sales as of March 2026, according to IQVIA.
Powered by Capital Market - Live News